Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
Virion has begun enrolling a multi-national, first-in-humans study, “VRON-0200,” for the treatment of persons with chronic hepatitis B virus (HBV) infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide.
- Virion has begun enrolling a multi-national, first-in-humans study, “VRON-0200,” for the treatment of persons with chronic hepatitis B virus (HBV) infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide.
- “We are pleased to be entering into this joint venture with Virion.
- We are also excited to help support their oncology program, which is targeted for IND submission in the next 9 months.
- We look forward to rolling up our sleeves together and bringing our novel therapeutics to patients worldwide!”